SCHEMBL25811720

SCHEMBL25811720

CN(CCN1CCOCC1)C(=O)c1ccc2[nH]c3c(c2c1)CCC3

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.49
MAPT P10636 5/20 0.49
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CASP1 P29466 2/20 0.49
CASP7 P55210 1/20 0.49
HSD17B10 Q99714 1/20 0.49
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
PARP1 P09874 4/20 0.47
POLB P06746 3/20 0.47
TP53 P04637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 1/20 0.43
F2 P00734 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25811965 0.98 MAPT (0.52) KDRMAPTALDH1A1KDM4EMEN1
SCHEMBL25811972 0.92 LMNA (0.51) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL25815140 0.90 MEN1 (0.49) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL25812002 0.90 KDM4E (0.54) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL25811968 0.90 LMNA (0.54) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL25811982 0.89 MAPT (0.53) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL25811835 0.88 LMNA (0.52) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL25813810 0.82 KDM4E (0.56) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL25814483 0.82 ALDH1A1 (0.53) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL25815092 0.80 KDM4E (0.59) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 KDR 4489/4885MAPT 18/4885ALDH1A1 4430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.